Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826006 | 0.82 | KMT2A (0.40) | KMT2AMAPTMEN1LMNASMN1; SMN2 | |
| SCHEMBL27494177 | 0.80 | MAPT (0.39) | KMT2AMAPTMEN1LMNASMN1; SMN2 | |
| SCHEMBL11467967 | 0.79 | PTPN1 (0.34) | GABRA1GABRB2S100B | |
| SCHEMBL5348348 | 0.79 | S100B (0.43) | KMT2AMAPTMEN1LMNASMN1; SMN2 | |
| SCHEMBL16815119 | 0.76 | KMT2A (0.42) | KMT2AMAPTMEN1LMNASMN1; SMN2 | |
| SCHEMBL11467966 | 0.74 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL8061571 | 0.73 | S100B (0.49) | KMT2AMAPTMEN1TDP1S100B | |
| SCHEMBL6429126 | 0.73 | TDP1 (0.39) | KMT2AMAPTMEN1LMNASMN1; SMN2 | |
| SCHEMBL6312333 | 0.72 | MEN1 (0.35) | KMT2AMAPTMEN1LMNAGABRA1 | |
| SCHEMBL7494519 | 0.72 | TDP1 (0.38) | KMT2AMAPTMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849766-B2 | 1,4-diamino-2-alkenylbenzene derivatives, and dyes containing these compounds | WELLA AKTIENGESELLSCHAFT (DE) | 2005-02-01 | — | — | US | disclosed |
| EP-1351921-B1 | NOVEL 1,4-DIAMINO-2-ALKENYL-BENZENE DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS | WELLA AG (DE) | 2004-12-01 | — | — | EP | disclosed |
| EP-1351921-A1 | NOVEL 1,4-DIAMINO-2-ALKENYL-BENZENE DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS | Wella Aktiengesellschaft (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030121110-A1 | Novel 1,4-diamino-2-alkenylbenzene derivatives , and dyes containing these compounds | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2003-07-03 | — | — | US | disclosed |
| WO-2002057214-A1 | NOVEL 1,4-DIAMINO-2-ALKENYL-BENZENE DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030121110-A1 | Novel 1,4-diamino-2-alkenylbenzene derivatives , and dyes containing these compounds | AOC1, AOX1, GPX1 | KMT2A 3908/4885MAPT 818/4885MEN1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.